LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of April 16, 2026, LXRX stock price declined to $1.84 with 1,918,088 million shares trading.

LXRX has a beta of 0.43, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.00 to the broad based SPY ETF.

LXRX has a market cap of $779.57 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $5 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.

In the last 3 years, LXRX traded as high as $3.79 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, VHT.

LXRX has outperformed the market in the last year with a price return of +259.3% while the SPY ETF gained +31.9%. LXRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.8% and +12.2%, respectively, while the SPY returned +1.6% and +7.1%, respectively.

LXRX support price is $1.79 and resistance is $1.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.